Who Buys Montelukast from India — 1324 Importers Behind a $168.3M Market

The importers of Montelukast from India can be categorized into several key segments:

1. Distributors: These entities purchase Montelukast in bulk to supply to various healthcare providers, pharmacies, and retailers. Their buying behavior is characterized by large-volume orders and a focus on cost-effectiveness to maintain competitive pricing. For instance, AMERISOURCE HEALTH SERVICES in the United States, with imports totaling $29.20 million, exemplifies this segment.

2. Pharmaceutical Companies: Companies like MACLEODS PHARMA USA, INC, which imported $25.30 million worth of Montelukast, may use the imported product for further processing, packaging, or direct distribution under their brand names. Their procurement patterns often involve consistent, large-scale purchases to meet production and market demands.

3. Hospital Groups and Healthcare Providers: These buyers procure Montelukast to meet the therapeutic needs of their patients. Their purchasing behavior is typically characterized by regular, moderate-sized orders aligned with patient demand and treatment protocols. While specific hospital groups are not listed among the top buyers, entities like THE CATHAY DRUG CO. INC in the Philippines, with imports of $4.16 million, may serve as suppliers to such institutions.

4. Government Procurement Agencies: Government bodies and international organizations often procure Montelukast through tenders to supply public health facilities and programs. Their buying patterns are influenced by public health policies, disease prevalence, and budget allocations. Although specific government agencies are not detailed in the top buyers, the presence of countries like the Philippines and Sri Lanka among the top importers suggests active government procurement.

5. Re-exporters: Some companies import Montelukast with the intent to re-export to other markets. Their purchasing behavior is driven by global market demands and trade agreements. Specific re-exporters are not identified in the provided data.

6. Contract Manufacturers: These entities import Montelukast to manufacture finished pharmaceutical products on behalf of other companies. Their procurement is typically large-scale and consistent, aligned with contractual obligations. While not explicitly listed, companies like UNICHEM PHARMACEUTICALS (USA) INC., with imports totaling $6.34 million, may operate in this capacity.

Understanding the import regulations for Montelukast in the top importing countries is crucial for market entry and compliance.

The demand for Montelukast in importing countries is influenced by several factors:

1. Disease Prevalence: Montelukast is primarily used to manage asthma and allergic rhinitis. According to the World Health Organization (WHO), asthma affected an estimated 262 million people globally in 2019, leading to 461,000 deaths. The high prevalence of respiratory conditions in countries like the United States and the Philippines drives the demand for effective treatments like Montelukast.

2. Government Healthcare Programs and Universal Health Coverage (UHC): Many countries are expanding their healthcare programs to achieve UHC, increasing access to essential medicines. For instance, the Philippines' Universal Health Care Act, enacted in 2019, aims to provide equitable access to quality and affordable health services, including essential medications. Such initiatives boost the procurement and distribution of drugs like Montelukast.

3. WHO Essential Medicines List (EML) Procurement: Montelukast is included in the WHO Model List of Essential Medicines, which guides countries in selecting medicines for their national formularies. Inclusion in the EML encourages governments and healthcare organizations to prioritize its procurement, ensuring wider availability.

4. Tender-Based Purchasing: Many countries and international organizations procure pharmaceuticals through tender systems to ensure cost-effectiveness and supply chain efficiency. For example, the WHO's Global Fund often utilizes tendering processes to procure medicines for large-scale health programs. Such mechanisms create substantial market opportunities for Montelukast suppliers.

With 1,324 buyers across 138 countries, the global market for Montelukast presents significant opportunities. Understanding the regulatory landscapes, demand drivers, and procurement mechanisms in key importing countries is essential for stakeholders aiming to navigate and succeed in this market.

The importers of Montelukast from India can be categorized into several key segments:

1. Distributors: These entities purchase Montelukast in bulk to supply to various healthcare providers, pharmacies, and retailers. Their buying behavior is characterized by large-volume orders and a focus on cost-effectiveness to maintain competitive pricing. For instance, AMERISOURCE HEALTH SERVICES in the United States, with imports totaling $29.20 million, exemplifies this segment.

2. Pharmaceutical Companies: Companies like MACLEODS PHARMA USA, INC, which imported $25.30 million worth of Montelukast, may use the imported product for further processing, packaging, or direct distribution under their brand names. Their procurement patterns often involve consistent, large-scale purchases to meet production and market demands.

3. Hospital Groups and Healthcare Providers: These buyers procure Montelukast to meet the therapeutic needs of their patients. Their purchasing behavior is typically characterized by regular, moderate-sized orders aligned with patient demand and treatment protocols. While specific hospital groups are not listed among the top buyers, entities like THE CATHAY DRUG CO. INC in the Philippines, with imports of $4.16 million, may serve as suppliers to such institutions.

4. Government Procurement Agencies: Government bodies and international organizations often procure Montelukast through tenders to supply public health facilities and programs. Their buying patterns are influenced by public health policies, disease prevalence, and budget allocations. Although specific government agencies are not detailed in the top buyers, the presence of countries like the Philippines and Sri Lanka among the top importers suggests active government procurement.

5. Re-exporters: Some companies import Montelukast with the intent to re-export to other markets. Their purchasing behavior is driven by global market demands and trade agreements. Specific re-exporters are not identified in the provided data.

6. Contract Manufacturers: These entities import Montelukast to manufacture finished pharmaceutical products on behalf of other companies. Their procurement is typically large-scale and consistent, aligned with contractual obligations. While not explicitly listed, companies like UNICHEM PHARMACEUTICALS (USA) INC., with imports totaling $6.34 million, may operate in this capacity.

Understanding the import regulations for Montelukast in the top importing countries is crucial for market entry and compliance.

The demand for Montelukast in importing countries is influenced by several factors:

1. Disease Prevalence: Montelukast is primarily used to manage asthma and allergic rhinitis. According to the World Health Organization (WHO), asthma affected an estimated 262 million people globally in 2019, leading to 461,000 deaths. The high prevalence of respiratory conditions in countries like the United States and the Philippines drives the demand for effective treatments like Montelukast.

2. Government Healthcare Programs and Universal Health Coverage (UHC): Many countries are expanding their healthcare programs to achieve UHC, increasing access to essential medicines. For instance, the Philippines' Universal Health Care Act, enacted in 2019, aims to provide equitable access to quality and affordable health services, including essential medications. Such initiatives boost the procurement and distribution of drugs like Montelukast.

3. WHO Essential Medicines List (EML) Procurement: Montelukast is included in the WHO Model List of Essential Medicines, which guides countries in selecting medicines for their national formularies. Inclusion in the EML encourages governments and healthcare organizations to prioritize its procurement, ensuring wider availability.

4. Tender-Based Purchasing: Many countries and international organizations procure pharmaceuticals through tender systems to ensure cost-effectiveness and supply chain efficiency. For example, the WHO's Global Fund often utilizes tendering processes to procure medicines for large-scale health programs. Such mechanisms create substantial market opportunities for Montelukast suppliers.

With 1,324 buyers across 138 countries, the global market for Montelukast presents significant opportunities. Understanding the regulatory landscapes, demand drivers, and procurement mechanisms in key importing countries is essential for stakeholders aiming to navigate and succeed in this market.